Ozempic

News

Novo Nordisk looks set to add another string to Ozempic bow

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabete

News

Could Novo-Catalent deal face antitrust hurdles?

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities

News

Novo Nordisk tackles supply issues with $11bn Catalent deal

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging

News

Novo Nordisk sales surge drives value towards $500bn

Fuelled by its diabetes and obesity drugs, Novo Nordisk has reported revenues up a third in 2023, sparking a rise in an already inflated share price that briefly pushed th

News

Novo Nordisk will invest €2.1bn in French manufacturing site

Novo Nordisk has made another major capital investment in production capacity for its diabetes and obesity therapies, agreeing to spend €2.1 billion ($2.3 billion) on a fa

News

Novo Nordisk sets aside $6bn to boost production capacity

Novo Nordisk is leaving nothing to chance when it comes to claiming a stake in the burgeoning market for diabetes and obesity therapies, announcing a plan to spend a whopp

Novo Nordisk looks set to add another string to Ozempic bow

Could Novo-Catalent deal face antitrust hurdles?

Novo Nordisk tackles supply issues with $11bn Catalent deal

Novo Nordisk sales surge drives value towards $500bn

Novo Nordisk will invest €2.1bn in French manufacturing site

Novo Nordisk sets aside $6bn to boost production capacity

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Ozempic

Editor's Picks